<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01752205</url>
  </required_header>
  <id_info>
    <org_study_id>ESCC-307PLAH-XJM</org_study_id>
    <nct_id>NCT01752205</nct_id>
  </id_info>
  <brief_title>Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma</brief_title>
  <acronym>ESCC-307PLAH</acronym>
  <official_title>A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and effectiveness of erlotinib and
      chemoradiotherapy in patients with unresectable esophageal or gastro-esophageal squamous
      cancer .
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Esophageal Squamous Carcinoma</condition>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV ï¼Œdosing schedule: 45mg/m2/w.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib and chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV (45mg/m2/w) and erlotinib PO QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>45mg/m2/w,total 6 weeks</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_label>Erlotinib and chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150mg/d,days 1-42,total 6 weeks</description>
    <arm_group_label>Erlotinib and chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_label>Erlotinib and chemoradiotherapy</arm_group_label>
    <other_name>radiation therapy QD, 5 days a week,95%PTV 60Gy/2Gy/30f,total 6 weeks</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed squamous cell carcinoma of esophagus or Esophagogastric
             Junction

          2. Age &gt;= 18

          3. ECOG PS 0-2

          4. Ineligibility for surgery

          5. No prior palliative therapy

          6. At least one bidimensionally measurable disease as defined by RECIST ver 1.1

          7. Adequate organ function for treatment

               -  Absolute neutrophil count (ANC)&gt;=1000cells/mm3

               -  Platelets &gt;=100000 cells/mm3

               -  Estimated creatinine clearance&gt;=50mL/min, or serum creatinine&lt;1.5 x institution
                  upper limit of normal

               -  Bilirubin=&lt;1.5 x upper limit of normal(ULN)

               -  AST(SGOT)=&lt;2.5 x ULN (5.0xULN if hepatic metastases)

               -  ALT(SGPT)=&lt;2.5 x ULN (5.0xULN if hepatic metastases)

               -  12-Lead electrocardiogram(ECG) with normal tracing or non-clinically significant
                  changes that do not require medical intervention

               -  QTc interval =&lt;470 msec and without history of Torsades de Points or other
                  symptomatic QTc abnormality

               -  LVEF (by MUGA or echocardiogram) of &gt;=50%.

          8. The patient has provided signed informed consent and is amenable to compliance with
             protocol schedules and testing.

        Exclusion Criteria:

          1. Previous treatment with small molecule EGFR tyrosine kinase inhibitors

          2. Any major operation within 4 weeks of baseline disease assessment

          3. Any clinically significant gastrointestinal abnormalities which may impair intake or
             absorption of the study drug

          4. CNS metastasis with continuous corticosteroid use within 4 weeks of baseline disease
             assessment

          5. Patients with known interstitial lung disease

          6. Patients with uncontrolled or significant cardiovascular disease (AMI within 12
             months,Unstable angina within 6 months, NYHA Class III, IV Congestive heart failure or
             left ventricular ejection fraction below local institutional lower limit of normal or
             below 45%, Congenital long QT syndrome, Any significant ventricular arrhythmia, Any
             uncontrolled second or third degree heart block, Uncontrolled hypertension)

          7. Previous or concurrent malignancy except for basal or squamous cell skin cancer and/or
             in situ carcinoma of the cervix, or other solid tumors treated curatively and without
             evidence of recurrence for at least 5 years prior to study entry.

          8. Pregnant or breast-feeding women

          9. Other severe acute or chronic medical condition or laboratory abnormality that may
             increase the risk associated with trial participation or investigational product
             administration or may interfere with the interpretation of trial results and, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xu jianming, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Hospital of the Chinese Academy of Military Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu jianming, M.D.</last_name>
    <phone>861051128358</phone>
    <email>jmxu2003@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>307 Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu jianming, M.D.</last_name>
      <phone>86-10-66947176</phone>
      <email>jmxu2003@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhao chuanhua</last_name>
      <phone>86-10-66947179</phone>
      <email>chuanhuazhao@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhao chuanhua</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2012</study_first_submitted>
  <study_first_submitted_qc>December 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2012</study_first_posted>
  <last_update_submitted>December 16, 2012</last_update_submitted>
  <last_update_submitted_qc>December 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</investigator_affiliation>
    <investigator_full_name>Xu jianming</investigator_full_name>
    <investigator_title>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</investigator_title>
  </responsible_party>
  <keyword>Esophageal Squamous Carcinoma</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

